BTIG analyst Matthew Vanvliet upgrades Agilysys (NASDAQ:AGYS) from Neutral to Buy.
Molecular Templates Presents Interim Data From MT-6402 Phase I Study In Patients With PD-L1+ Solid Tumors At 2024 AACR Annual Meeting
The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:MT-6402 has been well tolerated with no drug-related Grade 4 or Grade 5 adverse events observed MT-6402 acts uniquely
